Home/Pipeline/PRI-002

PRI-002

Alzheimer's Disease

Phase 2Active

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 2

Status

Active

Company

Priavoid

About Priavoid

Priavoid is a clinical-stage biotech pioneering a unique 'detangler' approach to treat neurodegenerative diseases by disassembling neurotoxic protein aggregates. Its proprietary platform generates all-D-peptides, which are orally available, non-immunogenic, and can reach targets in the brain. The pipeline includes a Phase 2 candidate for Alzheimer's (PRI-002), a program for synucleinopathies like Parkinson's (PRI-101), and a preclinical tau-targeting program (PRI-200), positioning the company at the forefront of a novel therapeutic modality for these challenging conditions.

View full company profile

Therapeutic Areas

Neurodegenerative Disorders Alzheimer's Disease Parkinson's Disease Multiple System Atrophy Amyotrophic Lateral Sclerosis

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active